Tuesday, 19 February 2019


GENERAL: TRU: TruScreen Receives CFDA Approval for its Second Generation

04 Dec 2017 16:09NZX
NZX and Media Release
4 December, 2017

NZX Limited

TruScreen Receives CFDA Approval for its Second Generation Device in China

Cervical cancer screening technology company, TruScreen Limited (NZAX:TRU) is
pleased to advise that the China Food and Drug Administration (CFDA) have
issued its formal certificate of approval permitting the commercial supply
and sale in China of the new upgraded TruScreen2 cervical cancer screening

TruScreen CEO Mr Martin Dillon said "CFDA registration is, by global
standards, an extremely rigorous validation process which certifies the
engineering, quality and  efficacy of our product for use in our major market
, China. The company has been steadily building up its inventories in
anticipation of receiving the registration and will now commence export sales
of the new device to China as soon as practicably possible."

For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com

Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen''s real time cervical cancer technology utilises a digital wand
which is placed on the surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between normal and abnormal (cancerous and
precancerous) tissue to identify precancerous change, or cervical
intraepithelial neoplasia (CIN).  A Single Use Sensor (SUS) is used for each
patient to protect against cross-infection.
End CA:00311379 For:TRU    Type:GENERAL    Time:2017-12-04 16:09:50
Views: 93
TruScreen Limited Ordinary Shares
 0.1850 Change:
Last Traded:07/02/18 09:15:21 
52-Wk High:0.2300 
52-Wk Low:0.1200